Effect of Obesogenic Medications on Weight-Loss Outcomes in a Behavioral Weight-Management Program
Effect of Obesogenic Medications on Weight-Loss Outcomes in a Behavioral Weight-Management Program
复制标题
DOI：
10.1002/oby.22444
复制
发表时间：
2019-05-01
期刊：
影响因子：
6.9
通讯作者：
Zarrinpar, Amir
中科院分区：
文献类型：
--
作者：
Desalermos, Athanasios;Russell, Baylee;Zarrinpar, Amir
目的本研究旨在评估行为体重管理计划中肥胖药物的使用与体重减轻不足之间的可能联系。方法这是一项病例对照、单中心研究，研究对象为退伍军人健康管理局卫生系统中参与搬迁的666名成年患者。行为减肥计划。队列被分为有反应的患者(n=150)，这些患者在搬家结束前体重下降了5%！计划组和无反应组(n=516)，总体重下降5%。我们查阅了每个患者在治疗期间暴露于肥胖药物的医疗记录。结果约62%(n=411)的患者进入MOVE！有一张肥胖症药物的处方。肥胖药物的使用与较差的减肥结果相关，参与者在移动结束时实现临床有意义的结果(总体重减轻5%)的可能性降低37%！方案(优势比，0.633；95%可信区间：0.427-0.937；调整后P=0.022)。与对照组相比，接受三种或三种以上药物治疗的患者(n=72)体重减轻5%的难度最大(优势比为0.265；95%可信区间：0.108-0.646；调整后的P=0.003)。结论：在行为性减肥计划中，使用供应商处方的肥胖药物与较差的减肥结果相关。为了帮助改善减肥治疗的结果，有必要对患者的药物进行更仔细的审查。
Objective This study aimed to evaluate a possible association between the use of obesogenic medications and inadequate weight loss in a behavioral weight-management program. Methods This is a case-control, single-center study of 666 adult patients within a Veterans Health Administration health system who participated in the MOVE! behavioral weight-loss program. The cohort was divided into responders (n = 150), patients who achieved >= 5% total weight loss by the end of the MOVE! program, and nonresponders (n = 516), those who achieved < 5% total weight loss. We reviewed each patient's medical records for exposure to obesogenic medication during the time of treatment. Results Approximately 62% (n = 411) of patients entering MOVE! had a prescription for obesogenic medications. Obesogenic medication use was associated with worse weight-loss outcomes, and participants were 37% less likely to achieve a clinically meaningful (>= 5% total weight loss) outcome at the end of the MOVE! program (odds ratio, 0.633; 95% CI: 0.427-0.937; adjusted P = 0.022). Patients who received three or more medications (n = 72) had the greatest difficulty achieving 5% weight loss compared with the control group (odds ratio, 0.265; 95% CI: 0.108-0.646; adjusted P = 0.003). Conclusions The use of provider-prescribed obesogenic medications was associated with worse weight-loss outcomes in a behavioral weight-loss program. Closer scrutiny of patient medications is necessary to help improve outcomes of weight-loss treatments.